← Human Trials & Peer-Reviewed Studies
Prognostic Impact of B-Type Natriuretic Peptide on Long-Term Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Myocardial Infarction Without Creatine Kinase Elevation
Plain-language guide to PMID 32921675 (2020): multicenter observational study of BNP (Nesiritide) in 3,283 patients.
Key Facts
- PMID
- 32921675
- Journal
- International heart journal
- Year
- 2020
- Study type
- Observational Study
- Authors
- Takahashi N et al. (35 authors)
- DOI
- 10.1536/ihj.20-190
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as an observational study.
Although B-type natriuretic peptide (BNP) has gradually gained recognition as an indicator in risk stratification for patients with acute myocardial infarction (AMI), the prognostic impact on long-term clinical outcomes in patients with non-ST-segment elevation acute myocardial infarction (NSTEMI) without creatine kinase (CK) elevation remains unclear.This prospective multicenter study assessed 3,283 consecutive patients with AMI admitted to 28 institutions in Japan between 2012 and 2014.
The researchers analyzed 218 patients with NSTEMI without CK elevation (NSTEMI-CK) for whom BNP was available.
Who Took Part
The abstract describes 3,283 patients taking part.
The age groups tagged for this paper are older adults and people over 80, both men and women.
In the NSTEMI-CK group, patients were assigned to high- and low-BNP groups according to BNP values (cut-off BNP, 100 pg/mL).
How the Study Was Run
The design is described as multicenter.
More than one site took part, so the patients came from several places.
What Was Measured
Although B-type natriuretic peptide (BNP) has gradually gained recognition as an indicator in risk stratification for patients with acute myocardial infarction (AMI), the prognostic impact on long-term clinical outcomes in patients with non-ST-segment elevation acute myocardial infarction (NSTEMI) without creatine kinase (CK) elevation remains unclear.This prospective multicenter study assessed 3,283 consecutive patients with AMI admitted to 28 institutions in Japan between 2012 and 2014.
PubMed files the paper under topics including Angina, Unstable, Cause of Death, Creatine Kinase, Heart Failure, Japan, Mortality and Myocardial Infarction.
Author keywords: Acute coronary syndrome, Asian, Percutaneous coronary intervention and Predictor.
What This Means in Plain Language
The paper is a multicenter study of BNP (Nesiritide) in 3,283 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2020 (International heart journal), a journal based in Japan.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.